Literature DB >> 18591218

Expression of CYP4A1 in U251 human glioma cell induces hyperproliferative phenotype in vitro and rapidly growing tumors in vivo.

Austin M Guo1, Ju Sheng, Gloria M Scicli, Ali S Arbab, Norman L Lehman, Paul A Edwards, John R Falck, Richard J Roman, A Guillermo Scicli.   

Abstract

Exogenous 20-hydroxyeicosatetraenoic acid (20-HETE) increases the growth of human glioma cells in vitro. However, glioma cells in culture show negligible 20-HETE synthesis. We examined whether inducing the expression of a 20-HETE synthase in a human glioma U251 cell line would increase proliferation. U251 cells transfected with CYP4A1 cDNA (termed U251 O) increased the formation of 20-HETE from less than 1 to over 60 pmol/min/mg proteins and increased their proliferation rate by 2-fold (p < 0.01). Compared with control U251, U251 O cells were rounded, smaller, showed a disorganized cytoskeleton, exhibited reduced vinculin staining, and were easily detached from the growing surface. They showed a marked increase in dihydroethidium staining, suggesting increased oxidative stress. The expression of phosphorylated extracellular signal-regulated kinase 1/2, cyclin D1/2, and vascular endothelial growth factor was markedly elevated in U251 O. The hyperproliferative and signaling effects seen in U251 O cells are abolished by selective CYP4A inhibition of 20-HETE formation with HET0016 [N-hydroxy-N'-(4-butyl-2-methylphenyl)-formamidine], by small interfering RNA against the enzyme, and by the putative 20-HETE antagonist, 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid. In vivo, implantation of U251O cells in the brain of nude rats resulted in a approximately 10-fold larger tumor volume (10 days postimplantation) compared with animals receiving mock-transfected U251 cells. These data show that elevations in 20-HETE synthesis in U251 cells lead to an increased growth both in vitro and in vivo. This suggests that 20-HETE may have proto-oncogenic properties in U251 human gliomas. Further studies are needed to determine whether 20-HETE plays a role promoting growth of some human gliomas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18591218      PMCID: PMC2636507          DOI: 10.1124/jpet.108.140889

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  31 in total

Review 1.  Biochemical and molecular properties of the cytochrome P450 arachidonic acid monooxygenases.

Authors:  Jorge H Capdevila; John R Falck
Journal:  Prostaglandins Other Lipid Mediat       Date:  2002-08       Impact factor: 3.072

Review 2.  The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions.

Authors:  Seunghee Yoon; Rony Seger
Journal:  Growth Factors       Date:  2006-03       Impact factor: 2.511

3.  Inhibitors of cytochrome P450 4A suppress angiogenic responses.

Authors:  Ping Chen; Meng Guo; Dana Wygle; Paul A Edwards; John R Falck; Richard J Roman; A Guillermo Scicli
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

4.  Production of 20-HETE and its role in autoregulation of cerebral blood flow.

Authors:  D Gebremedhin; A R Lange; T F Lowry; M R Taheri; E K Birks; A G Hudetz; J Narayanan; J R Falck; H Okamoto; R J Roman; K Nithipatikom; W B Campbell; D R Harder
Journal:  Circ Res       Date:  2000-07-07       Impact factor: 17.367

Review 5.  Mammalian cyclin-dependent kinases.

Authors:  Marcos Malumbres; Mariano Barbacid
Journal:  Trends Biochem Sci       Date:  2005-10-19       Impact factor: 13.807

Review 6.  Kidney CYP450 enzymes: biological actions beyond drug metabolism.

Authors:  X Zhao; J D Imig
Journal:  Curr Drug Metab       Date:  2003-02       Impact factor: 3.731

7.  Glial cells dilate and constrict blood vessels: a mechanism of neurovascular coupling.

Authors:  Monica R Metea; Eric A Newman
Journal:  J Neurosci       Date:  2006-03-15       Impact factor: 6.167

Review 8.  Redox control of cell death.

Authors:  Shugo Ueda; Hiroshi Masutani; Hajime Nakamura; Toru Tanaka; Masaya Ueno; Junji Yodoi
Journal:  Antioxid Redox Signal       Date:  2002-06       Impact factor: 8.401

Review 9.  Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology.

Authors:  David Sacerdoti; Angelo Gatta; John C McGiff
Journal:  Prostaglandins Other Lipid Mediat       Date:  2003-10       Impact factor: 3.072

10.  Effects of a 20-HETE antagonist and agonists on cerebral vascular tone.

Authors:  Ming Yu; Liana Cambj-Sapunar; Franz Kehl; Kristopher G Maier; Kazuhiko Takeuchi; Noriyuki Miyata; Tsuyoshi Ishimoto; L Manmohan Reddy; John R Falck; Debebe Gebremedhin; David R Harder; Richard J Roman
Journal:  Eur J Pharmacol       Date:  2004-02-23       Impact factor: 4.432

View more
  27 in total

1.  GPR75 receptor mediates 20-HETE-signaling and metastatic features of androgen-insensitive prostate cancer cells.

Authors:  Sofia Cárdenas; Cecilia Colombero; Laura Panelo; Rambabu Dakarapu; John R Falck; Monica A Costas; Susana Nowicki
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2019-11-21       Impact factor: 4.698

Review 2.  EET signaling in cancer.

Authors:  Dipak Panigrahy; Emily R Greene; Ambra Pozzi; Dao Wen Wang; Darryl C Zeldin
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

3.  Down-regulation of 20-HETE synthesis and signaling inhibits renal adenocarcinoma cell proliferation and tumor growth.

Authors:  Anna Alexanian; Victoriya A Rufanova; Bradley Miller; Averia Flasch; Richard J Roman; Andrey Sorokin
Journal:  Anticancer Res       Date:  2009-10       Impact factor: 2.480

4.  Cytochrome P450 ω-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancer.

Authors:  Wei Yu; Li Chen; Yu-Qing Yang; John R Falck; Austin M Guo; Ying Li; Jing Yang
Journal:  Cancer Chemother Pharmacol       Date:  2010-12-01       Impact factor: 3.333

Review 5.  Regulation of inflammation in cancer by eicosanoids.

Authors:  Emily R Greene; Sui Huang; Charles N Serhan; Dipak Panigrahy
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-08-16       Impact factor: 3.072

6.  Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer.

Authors:  Wei Yu; Hongyan Chai; Ying Li; Haixia Zhao; Xianfei Xie; Hao Zheng; Chenlong Wang; Xue Wang; Guifang Yang; Xiaojun Cai; John R Falck; Jing Yang
Journal:  Toxicol Appl Pharmacol       Date:  2012-07-25       Impact factor: 4.219

Review 7.  Cytochrome P450-derived eicosanoids: the neglected pathway in cancer.

Authors:  Dipak Panigrahy; Arja Kaipainen; Emily R Greene; Sui Huang
Journal:  Cancer Metastasis Rev       Date:  2010-12       Impact factor: 9.264

8.  Combined therapy with COX-2 inhibitor and 20-HETE inhibitor reduces colon tumor growth and the adverse effects of ischemic stroke associated with COX-2 inhibition.

Authors:  Yi Zhang; Md Nasrul Hoda; Xuan Zheng; Weiguo Li; Pengcheng Luo; Krishna Rao Maddipati; Tsugio Seki; Adviye Ergul; Mong-Heng Wang
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-07-02       Impact factor: 3.619

9.  20-HETE activates the Raf/MEK/ERK pathway in renal epithelial cells through an EGFR- and c-Src-dependent mechanism.

Authors:  Talha Akbulut; Kevin R Regner; Richard J Roman; Ellis D Avner; John R Falck; Frank Park
Journal:  Am J Physiol Renal Physiol       Date:  2009-07-01

10.  Preparation of 20-HETE using multifunctional enzyme type 2-negative Starmerella bombicola.

Authors:  Inge Van Bogaert; Guodong Zhang; Jun Yang; Jun-Yan Liu; Yonghao Ye; Wim Soetaert; Bruce D Hammock
Journal:  J Lipid Res       Date:  2013-08-21       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.